Wedbush Cuts Price Target on Stericycle (SRCL) to $82; Reiterates Neutral

November 14, 2016 7:54 AM EST
Get Alerts SRCL Hot Sheet
Price: $72.00 --0%

Rating Summary:
    9 Buy, 10 Hold, 3 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade SRCL Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Wedbush maintained a Neutral rating on Stericycle (NASDAQ: SRCL), and cut the price target to $82.00 (from $85.00), following the company's investor day. Management clarified the impact from the pricing environment within RMW and specifically the small quantity generator headwinds.

Analyst Al Kaschalk commented, "Despite being forthright with headwinds in the current environment during its investor day, Stericycle’s (SRCL) five-year strategic outlook of calling for organic EPS compounded annual growth rate (CAGR) of 4-8% on sales growth of 3-5% is back-end weighted. Continuous improvement, growth drivers in small healthcare provider segment and acquisitions could add 3-5 percentage points implying EPS CAGR of 7-13% over the forecast period. While the EPS CAGR is generally consistent with the 10-14% we were looking for ahead of the analyst day, annual EPS growth is expected to struggle to exceed 3-4% before mid-CY18. Accordingly, we would avoid shares of SRCL until there is improved pricing environment within core medical waste business, strategic rationale for hazardous waste network (primarily industrial footprint) is completed and International platform enjoys added services to its existing customer base."

For an analyst ratings summary and ratings history on Stericycle click here. For more ratings news on Stericycle click here.

Shares of Stericycle closed at $75.00 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Related Entities

Al Kaschalk

Add Your Comment